[1] Q. N. Baito, H. M. Jaafar, and T. A. M. Mohammad, "Piperine suppresses inflammatory fibroblast-like synoviocytes derived from rheumatoid arthritis patients Via NF-κB inhibition," Cellular Immunology, vol. 391, p. 104752, 2023.
[2] M. Gulati, Z. Farah, and M. Mouyis, "Clinical features of rheumatoid arthritis," Medicine, vol. 46, no. 4, pp. 211-215, 2018.
[3] V. C. Romão and J. E. Fonseca, "Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review," Frontiers in medicine, vol. 8, p. 689698, 2021.
[4] M. Li, Z. Popovic, C. Chu, B. K. Krämer, and B. Hocher, "Endostatin in renal and cardiovascular diseases," Kidney Diseases, vol. 7, no. 6, pp. 468-481, 2021.
[5] M. Grant and R. Kallur, "Structural basis for the functions of endogenous angiogenesis inhibitors," in Cold Spring Harbor symposia on quantitative biology, 2005, vol. 70: Cold Spring Harbor Laboratory Press, pp. 399-417.
[6] Z. Szekanecz, T. Besenyei, G. Paragh, and A. E. Koch, "Angiogenesis in rheumatoid arthritis," Autoimmunity, vol. 42, no. 7, pp. 563-573, 2009.
[7] H. Wang, Y. Chen, X.-a. Lu, G. Liu, Y. Fu, and Y. Luo, "Endostatin prevents dietary-induced obesity by inhibiting adipogenesis and angiogenesis," Diabetes, vol. 64, no. 7, pp. 2442-2456, 2015.
[8] E. Kucharz et al., "A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis," Clinical and experimental rheumatology, vol. 21, no. 2, pp. 273-273, 2003.
[9] N. Y. Assaf, A. Faramawy, M. A. Bassett, and N. Elwan, "Possible role of serum levels of vascular endothelial growth factor and endostatin in rheumatoid arthritis angiogenesis imbalance," Egyptian Rheumatology and Rehabilitation, vol. 34, no. 3, pp. 417-426, 2007.
[10] R. L. Mirwald, A. D. Baxter-Jones, D. A. Bailey, and G. P. Beunen, "An assessment of maturity from anthropometric measurements," Medicine & science in sports & exercise, vol. 34, no. 4, pp. 689-694, 2002.
[11] X. Feng et al., "Body mass index and the risk of rheumatoid arthritis: an updated dose-response meta-analysis," BioMed research international, vol. 2019, 2019.
[12] M. M. Ismail and S. F. Alaaraji, "An exploration of the relationship between interleukin 37, 8-ohdg and a number of anthropometric measurements in iraqi rheumatoid arthritis patients," EurAsian Journal of BioSciences, vol. 14, no. 1, 2020.
[13] L. Bautista, L. Vera, I. Arenas, and G. Gamarra, "Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension," Journal of human hypertension, vol. 19, no. 2, pp. 149-154, 2005.
[14] J. A. Avina-Zubieta, J. Thomas, M. Sadatsafavi, A. J. Lehman, and D. Lacaille, "Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies," Annals of the rheumatic diseases, vol. 71, no. 9, pp. 1524-1529, 2012.
[15] S. Gabriel, "Heart disease in rheumatoid arthritis: changing the paradigm of systemic inflammatory disorders," The Journal of Rheumatology, vol. 34, no. 1, pp. 220-223, 2007.
[16] S. F. T. Alaaraji, "Exploration of the Relationship between Interleukins 17, 37 and 38 with Vitamin E in Iraqi Men with CHB," in Journal of Physics: Conference Series, 2019, vol. 1294, no. 5: IOP Publishing, p. 052047.
[17] H. S. Mahmoud and S. F. Alaaraji, "A relationship of contactin-1 with a number of trace elements in Iraqi rheumatoid arthritis patients with and without COVID-19."
[18] F. C. Arnett et al., "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis," Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, vol. 31, no. 3, pp. 315-324, 1988.
[19] A. Ardanny, "Pathophysiology and Management of Refractory Rheumatoid Arthritis: A Narrative Literature Review," Bioscientia Medicina: Journal of Biomedicine and Translational Research, vol. 8, no. 4, pp. 4239-4246, 2024.
[20] Y. Wang, H. Wu, and R. Deng, "Angiogenesis as a potential treatment strategy for rheumatoid arthritis," European Journal of Pharmacology, vol. 910, p. 174500, 2021.
[21] C. Faye, E. Chautard, B. R. Olsen, and S. Ricard-Blum, "The first draft of the endostatin interaction network," Journal of biological chemistry, vol. 284, no. 33, pp. 22041-22047, 2009.
[22] W. Hu et al., "Recombinant human endostatin inhibits adjuvant arthritis by down-regulating VEGF expression and suppression of TNF-α, IL-1β production," Inflammation Research, vol. 61, pp. 827-835, 2012.
[23] S. M. O’Brien, P. Fitzgerald, P. Scully, A. Landers, L. V. Scott, and T. G. Dinan, "Impact of gender and menstrual cycle phase on plasma cytokine concentrations," Neuroimmunomodulation, vol. 14, no. 2, pp. 84-90, 2007.
[24] H. J. Kadhim et al., "The Relationship between Obesity and Rheumatoid Arthritis," Journal of Current Medical Research and Opinion, vol. 6, no. 12, pp. 1914-1926, 2023.